JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2007; 50:32-36, doi:10.1016/j.jacc.2007.01.096 (Published online 17 June 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2007.01.096v1
50/1/32    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aguilar, D.
Right arrow Articles by Deswal, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Aguilar, D.
Right arrow Articles by Deswal, A.
Related Collections
Right arrowRelated Article

CLINICAL RESEARCH: HEART FAILURE

The Impact of Thiazolidinedione Use on Outcomes in Ambulatory Patients With Diabetes Mellitus and Heart Failure

David Aguilar, MD*,*, Biykem Bozkurt, MD, FACC*,{dagger}, Allison Pritchett, MD, FACC*, Nancy J. Petersen, PhD{dagger} and Anita Deswal, MD, MPH, FACC*,{dagger},{ddagger}

* Winters Center for Heart Failure Research and Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas
{dagger} Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
{ddagger} Houston Center for Quality of Care and Utilization Studies, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.

Manuscript received November 30, 2006; revised manuscript received January 11, 2007, accepted January 16, 2007.

* Reprint requests and correspondence: Dr. David Aguilar, Cardiovascular Division, Baylor College of Medicine, 1709 Dryden Street, BCM 620, Suite 500, Box 13, Houston, Texas 77030. (Email: daguilar{at}bcm.edu).

Objectives: This study sought to examine the relationship between thiazolidinedione (TZD) use and outcomes in ambulatory patients with diabetes and heart failure (HF).

Background: Thiazolidinediones have been relatively contraindicated in diabetic patients with HF.

Methods: We conducted a retrospective study of a national cohort of veterans with HF and diabetes treated in ambulatory clinics at Veterans Affairs medical centers. Patients were classified into those using TZDs and those not using insulin-sensitizing medication based on prescriptions filled 90 days before or 30 days after the index outpatient visit. The outcomes were time to hospitalization for HF and time to death.

Results: Of 7,147 ambulatory HF patients receiving diabetic therapy, 818 (11.4%) were receiving a TZD and 4,700 (65.8%) were not receiving insulin sensitizers. Over 2 years of follow-up, 134 (16.4%) patients receiving TZDs and 741 (15.8%) patients not receiving insulin-sensitizing medications required HF hospitalization (adjusted hazard ratio 1.00, 95% confidence interval 0.81 to 1.24, p = 0.97). A total of 168 (20.5%) patients receiving TZDs and 1,192 (25.4%) patients not receiving insulin-sensitizing medications died (adjusted hazard ratio 0.98, 95% confidence interval 0.81 to 1.17, p = 0.80).

Conclusions: In ambulatory patients with established HF and diabetes, the use of TZDs was not associated with an increased risk of HF hospitalization or total mortality when compared with those not receiving insulin-sensitizing medications.

Abbreviations and Acronyms
  CI = confidence interval
  COPD = chronic obstructive pulmonary disease
  EPRP = External Peer Review Program
  HF = heart failure
  HR = hazard ratio
  LVEF = left ventricular ejection fraction
  TZD = thiazolidinedione
  VA = Veterans Affairs


Related Article

Diabetes and Heart Failure: The Role of Thiazolidinediones in Managing These Partners in Crime
Carl V. Leier and Garrie J. Haas
J. Am. Coll. Cardiol. 2007 50: 37-39. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Eur Heart JHome page
M. R. MacDonald, M. C. Petrie, N. M. Hawkins, J. R. Petrie, M. Fisher, R. McKelvie, D. Aguilar, H. Krum, and J. J.V. McMurray
Diabetes, left ventricular systolic dysfunction, and chronic heart failure
Eur. Heart J., May 2, 2008; 29(10): 1224 - 1240.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. V. Leier and G. J. Haas
Diabetes and Heart Failure: The Role of Thiazolidinediones in Managing These Partners in Crime
J. Am. Coll. Cardiol., July 3, 2007; 50(1): 37 - 39.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2007 by the American College of Cardiology Foundation.